Description
PrymaLab · Research use only
GLOW BLEND 50MG
GHK-Cu 35 mg, BPC-157 5 mg and TB-500 10 mg: a 7:1:2 three-peptide blend vial
GLOW 50 mg combines three research peptides in one freeze-dried vial: the copper tripeptide GHK-Cu (35 mg), the gastric-derived pentadecapeptide BPC-157 (5 mg) and full-length thymosin beta-4, sold as TB-500 (10 mg). Its ratio differs from GLOW 70 mg, so it is a separate product. Each component has been studied alone, in cell culture and rodents; the blend itself has not been the subject of any published study.
Specifications
| Property | Value |
|---|---|
| Components | GHK-Cu (Copper tripeptide-1; Gly-His-Lys · Cu(II)) BPC-157 (Body Protection Compound-157; pentadecapeptide) TB-500 (Thymosin β4); N-acetyl thymosin β4, full-length 43-residue peptide |
| GHK-Cu CAS number | 89030-95-5 |
| BPC-157 CAS number | 137525-51-0 |
| TB-500 (Thymosin β4) CAS number | 77591-33-4 |
| Label claim | GHK-Cu 35 mg + BPC-157 5 mg + TB-500 (Thymosin β4) 10 mg (50 mg in total) |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Lot certificate | Results for the lot now shipping are in the certificate panel on this page |
| Safety data sheet | PL-SDS-069 |
How this vial differs from GLOW 70 mg
The certificate for this lot gives 35 mg of GHK-Cu, 5 mg of BPC-157 and 10 mg of N-acetyl thymosin beta-4, all three confirmed by LC-MS. Converted with the certificate’s theoretical masses, that is about 87 µmol of GHK-Cu, 3.5 µmol of BPC-157 and 2.0 µmol of thymosin beta-4. The GLOW 70 mg vial holds 50, 10 and 10 mg instead. Both contain the same 10 mg of thymosin beta-4, but here it sits beside half as much BPC-157 and less GHK-Cu, so thymosin beta-4 makes up a fifth of the vial by mass rather than a seventh.
The practical upshot is that the two vials cannot be interchanged by changing the diluent volume: no dilution of one reproduces the proportions of the other. Like every GHK-Cu product, the cake and its solutions are blue because of the copper complex.
What the research covers
Three peptides share this vial, but they share no literature. Every study summarised below tested one component alone, and no published work has looked at GLOW, or at GHK-Cu, BPC-157 and thymosin beta-4 together, in any model.
GHK-Cu: collagen and tissue repair
GHK-Cu is the copper complex of a tripeptide first isolated from human plasma1. The key cell study measured collagen made by fibroblasts in culture: output increased at concentrations as low as the picomolar range and peaked at one nanomolar while cell numbers stayed level, so the rise was in collagen per cell1. A 2018 review co-written by Loren Pickart reported that GHK supports dermal fibroblast function, increases elastin as well as collagen, and has improved tissue repair in skin, bone, liver, lung connective tissue and stomach lining2. The same review credits it with anti-inflammatory and anti-cancer activity and relates these to genetic data showing many biochemical pathways under GHK regulation2.
BPC-157: vessels and tendon
BPC-157 is a fifteen-amino-acid partial sequence of a protein first isolated from human gastric juice, previously reported to speed healing of transected rat Achilles tendon3. Working with explants and fibroblasts from that tendon, Chang’s group found faster outgrowth, more migration and spreading, and better survival under oxidative stress, though proliferation was unaffected3. In a separate line of work, Hsieh and colleagues linked the peptide to angiogenesis: vessel density rose in chick embryo membranes and endothelial tube assays, blood flow recovered faster in rat ischemic limbs, and VEGFR2 signalling through Akt and eNOS increased in human endothelial cells4. The receptor was also drawn into the cells, and dynasore, which blocks endocytosis, suppressed both the signalling and the extra tube formation4.
Thymosin beta-4: the actin buffer
The TB-500 component is the complete 43-residue thymosin beta-4, a member of a peptide family once thought to be thymic hormones5. Huff and colleagues described the beta-thymosins as small acidic peptides present at high concentration in almost every cell, where they hold actin monomers in a one-to-one complex and stop them polymerising until filaments are needed5. Changes in their expression appear to track cell differentiation5. Several extracellular effects have been attributed to thymosin beta-4, to an oxidised form and to its fragment Ac-SDKP, among them chemotaxis, angiogenesis and reduced inflammation5.
Limits of the evidence
For all three components, the work cited here was done in cells, chick embryos and rodents. The extracellular mechanisms of thymosin beta-4 were unknown when Huff’s group reviewed them5, and the GHK-Cu reviews come largely from the scientist who discovered the peptide. Nothing has been published on how these three behave mixed at a 7:1:2 ratio, or at any ratio. None of the studies used PrymaLab material, and the GLOW peptide guide discusses each literature at greater length.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. The results for the lot now shipping are in the certificate panel on this page, and the certificate number, key and QR code can be checked on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Why is GLOW 50 mg a separate product from GLOW 70 mg?
Because the ratio differs. This vial holds GHK-Cu 35 mg, BPC-157 5 mg and TB-500 10 mg (7:1:2); GLOW 70 mg holds 50, 10 and 10 mg (5:1:1). Each is made as its own lot with its own certificate, and neither can be turned into the other by dilution.
Which TB-500 is in the vial?
Full-length thymosin beta-4: 43 residues with an acetylated N-terminus and a free C-terminus, theoretical mass 4963.5 Da. Some sellers use the name TB-500 for a short synthetic fragment; the sequence and LC-MS confirmation on the certificate show which molecule this is.
How do I read a three-component certificate?
The certificate reports LC-MS identity as the number of components confirmed, three of three for the current lot, and gives purity by RP-HPLC, water content, endotoxin and sterility. Match the lot number on your vial to the certificate panel on this page, or check it on the verify page.
What does the research say about the blend?
Nothing directly. The published work studies GHK-Cu, BPC-157 and thymosin beta-4 separately, mostly in cell culture and rodents. No study has combined them, so their joint behaviour, in solution or in a model, is unknown.
How should the vial be kept?
Sealed at −20 °C, dry and away from light; warm it to room temperature before opening. After reconstitution, store the solution at 2 to 8 °C in the dark for a period your laboratory has validated. Expect it to be blue, from the copper complex.
Is GLOW 50 mg for human use?
No. It is laboratory research material only, with no FDA or other approval for human or veterinary use. It must not be given to people or animals in any form.
References
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. DOI · PubMed
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7). DOI · PubMed
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. DOI · PubMed
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. DOI · PubMed
- Huff T, Müller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-20. DOI · PubMed
Research use only
For laboratory research use only. GLOW BLEND 50MG is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of GLOW BLEND
GLOW BLEND is also stocked as GLOW BLEND 50mg/ml preloaded 3ml pen. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.